GlassScriptPhysician profile
Emma K Klein
NPI 1972276756
$3,273.31
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $386 · 2022: $1,457 · 2023: $1,310 · 2024: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,430.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $705.26 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $341.92 | 2021-2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.45 | 2021-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $174.93 | 2022-2023 | |
| Esperion Therapeutics, INC. | $173.67 | 2021-2022 | |
| Amgen INC. | $172.47 | 2022-2023 | Repatha |
| Edwards Lifesciences Corporation | $169.54 | 2022-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $161.69 | 2022-2023 | Lux-Dx Insertable Cardiac Monitor |
| Axonics, INC. | $157.49 | 2023 | Bulkamid, Axonics |
| Astrazeneca Pharmaceuticals LP | $139.77 | 2022 | |
| Lilly USA, LLC | $123.60 | 2022-2023 | Mounjaro |
| Smith+Nephew, INC. | $120.31 | 2024 | Stravix |
| Impulse Dynamics (USA) INC. | $89.98 | 2023 | Optimizer |
| Janssen Pharmaceuticals, INC | $70.41 | 2023 | Xarelto |
| Kiniksa Pharmaceuticals, LTD. | $67.22 | 2021-2023 | Arcalyst |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $46.04 | 2023 | Amvuttra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.28 | 2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $41.18 | 2021-2023 | Trintellix |
| Bsn Medical INC | $34.78 | 2022 | |
| Daiichi Sankyo INC. | $25.93 | 2023 | Injectafer |
| Amarin Pharma, INC. | $24.06 | 2022 | |
| Pfizer INC. | $21.50 | 2022 | |
| Vivus LLC | $21.33 | 2023 | Qsymia |
| Actelion Pharmaceuticals US, INC. | $19.30 | 2023 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $18.02 | 2022 | |
| Currax Pharmaceuticals LLC | $18.00 | 2022 | |
| Medtronic, INC. | $17.85 | 2022 | |
| Novo Nordisk INC | $17.34 | 2023 | Wegovy |
| Medicure Pharma INC. | $11.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.